高效抗逆转录病毒治疗艾滋病的生存时间及临床疗效分析  

Study of Survival Time and Clinical Efficacy of Highly Active Antiretroviral Therapy for HIV / AIDS

作　　者：吕日英[1] 李健龙 覃雄林 朱宇佳[1] 覃琼芬[1] 付少萍[1] 李仕雄[1] 许超宇[1] 江波[1] 

机构地区：[1]广西医科大学第八附属医院,广西贵港537100 [2]广西壮族自治区贵港市疾病控制中心,广西贵港537100

出　　处：《中国药业》2016年第3期7-9,共3页China Pharmaceuticals

基　　金：广西贵港市科学研究与技术开发计划;项目编号:贵科学攻关12090280

摘　　要：目的探讨艾滋病患者高效抗逆转录病毒治疗后生存时间、治疗效果和影响因素。方法收集贵港地区各抗病毒治疗点收治的3 100例艾滋病患者作为研究对象,患者均接受高效抗逆转录病毒治疗(HAART)治疗,采用COX比例风险模式对患者抗病毒治疗后生存期因素进行分析,分析影响HAART效果的危险因素。结果 3 100例患者中,146例确诊感染人类免疫缺陷病毒(HIV)后进行中医治疗,占4.71%;56.00%患者体重下降,35.81%患者持续发热;19.37%患者带状疱疹;11.58%患者持续腹泻;7.50%患者吞咽困难。190例死亡,占6.13%;76例停药,占2.45%;527例失访,占17.00%;2 307例继续治疗,占74.42%。通过多因素分析结果显示,治疗开始时CD_4^+T细胞水平数、入治时出现机会性感染种类数、平均每月漏服药物次数等为患者高效抗逆转录病毒治疗的影响因素(P<0.05)。结论 HAART治疗艾滋病效果理想,治疗过程中应采取有效措施监测患者CD_4^+T变化以及机会性感染情况,同时治疗过程中应加强药物教育,动态了解患者用药情况,并及时调整治疗方案。Objective To study the survival time, treatment effect and Influence factors of highly active antiretroviral therapy for the HIV/AIDS patients. Methods 3 100 cases of HIV/AIDS patients admitted in Guigang were collected as the research object, all pa- tients received HAART and adopted COX proportional hazards model to analyze the survival factors and the risk factors that influenced the effect of HAART. Results In the 3100 cases of patients, 146 cases of HIV infection received TCM treatment, accounting for 4.71% ; 56.00% suffered weight loss, 35.81% with persistent fever; 19. 37% zoster; 11.58% persistent diarrhea; 7.50% with dyspha- gia. 190 cases died, accounting for 6. 13%;76 cases stopped medication, accounting for 2.45%;527 cases were lost, accounting for 17.00%;2 307 cases continued treatment, accounting for 74. 42%. Multivariate analysis showed that treatment begin CD4＋ T cell count level, opportunistic infections occur when the number of types of treatment, the average monthly number of medication leakage as the in- fluential factors of the highly active antiretroviral therapy（ P 〈 0.05）. Conclusion HAART AIDS treatment has ideal efficacy. During the course of treatment effective measures to monitor changes in patients with CD4＋ T and opportunistic infection should be taken, drug education should be strengthened, and dynamic understanding of the patient should be achieved to make timely adjustment of the treatment.

关 键 词：艾滋病 高效抗逆转录病毒 生存时间 影响因素 疗效 

分 类 号：R969.4[医药卫生—药理学] R978.7[医药卫生—药学]